Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Am J Health Syst Pharm. 2022 Jun 23;79(13):1086-1095. doi: 10.1093/ajhp/zxac045.
Inaccurate and nonspecific medication alerts contribute to high override rates, alert fatigue, and ultimately patient harm. Drug-drug interaction (DDI) alerts often fail to account for factors that could reduce risk; further, drugs that trigger alerts are often inconsistently grouped into value sets. Toward improving the specificity of DDI alerts, the objectives of this study were to (1) highlight the inconsistency of drug value sets for triggering DDI alerts and (2) demonstrate a method of classifying factors that can be used to modify the risk of harm from a DDI.
This was a proof-of-concept study focused on 15 well-known DDIs. Using 3 drug interaction references, we extracted 2 drug value sets and any available order- and patient-related factors for each DDI. Fleiss' kappa was used to measure the consistency of value sets among references. Risk-modifying factors were classified as order parameters (eg, route and dose) or patient characteristics (eg, comorbidities and laboratory results).
Seventeen value sets (56%) had nonsignificant agreement. Agreement among the remaining 13 value sets was on average moderate. Thirty-three factors that could reduce risk in 14 of 15 DDIs (93%) were identified. Most risk-modifying factors (67%) were classified as order parameters.
This study demonstrates the importance of increasing the consistency of drug value sets that trigger DDI alerts and how alert specificity and usefulness can be improved with risk-modifying factors obtained from drug references. It may be difficult to operationalize certain factors to reduce unnecessary alerts; however, factors can be used to support decisions by providing contextual information.
不准确和非特异性的药物警示会导致高覆盖率、警示疲劳,最终导致患者受到伤害。药物-药物相互作用(DDI)警示往往没有考虑到可能降低风险的因素;此外,触发警示的药物通常不一致地分组到价值集中。为了提高 DDI 警示的特异性,本研究的目的是(1)强调触发 DDI 警示的药物价值集的不一致性,(2)展示一种可用于修改 DDI 危害风险的因素分类方法。
这是一项概念验证研究,专注于 15 种已知的 DDI。使用 3 种药物相互作用参考资料,我们提取了 2 种药物价值集和每种 DDI 的任何可用的医嘱和患者相关因素。Fleiss' kappa 用于衡量参考资料中价值集的一致性。风险修正因素被分类为医嘱参数(例如,途径和剂量)或患者特征(例如,合并症和实验室结果)。
17 个价值集(56%)具有无显著一致性。其余 13 个价值集的一致性平均为中度。在 15 个 DDI 中的 14 个(93%)确定了 33 个可以降低风险的因素。大多数风险修正因素(67%)被分类为医嘱参数。
本研究表明了增加触发 DDI 警示的药物价值集的一致性的重要性,以及如何通过从药物参考资料中获得的风险修正因素来提高警示的特异性和有用性。将某些因素付诸实施以减少不必要的警示可能很困难;然而,这些因素可以通过提供上下文信息来支持决策。